1250.1 - Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)

Page last updated: 11 July 2016

Application Detail

Status

Closed

Description of Medical Service

ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.

Description of Medical Condition

ALK-positive advanced NSCLC.

Reason for Application

-

Medical Service Type

-

Previous Application Number

1250

Associated Documentation

Application Form

-

PICO Confirmation

28 May 2012 – 5 July 2012
Consultation Protocol (PDF 250 KB)
Consultation Protocol (Word 740 KB)

Final Protocol (PDF 585 KB)
Final Protocol (Word 6128 KB)

Assessment Report

-

Public Summary Document

Public Summary Document - November 2014 Update (PDF 273 KB)
Public Summary Document - November 2014 Update (Word 111 KB)

Meetings for this Application

PASC

-

ESC

12 to 13 June 2014

MSAC

3 October 2014
26 to 28 November 2014